Previous 10 | Next 10 |
2023-09-25 09:00:00 ET Summary Revolution Medicines boasts a strong cash position of $909.5M and a focus on RAS-targeted oncology but faces increased expenses and high clinical expectations. Upcoming clinical data for RMC-6236 and the EQRx acquisition are key catalysts that could ...
KRAS G12D (ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRAS G12D mutation, the most common driver of RAS-addicted human cancers REDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc....
Science Report on KRAS G12C (ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology c...
2023-08-08 23:05:08 ET Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Conference Call August 08, 2023 4:30 PM ET Company Participants Erin Graves – Senior Director of Corporate Communications and Investor Relations Mark Goldsmith – Chairman and Chie...
2023-08-08 16:34:19 ET Revolution Medicines press release ( NASDAQ: RVMD ): Q2 GAAP EPS of -$0.92 misses by $0.09 . Revenue of $3.82M (-58.1% Y/Y) beats by $2.26M . For further details see: Revolution Medicines GAAP EPS of -$0.92 misses by $0.09, revenue ...
Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple Meeting Planning underway for one or more single agent pivotal trials with RMC-6236 and...
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August 8...
2023-08-01 08:32:02 ET A clinical-stage oncology company, Revolution Medicines ( NASDAQ: RVMD ) plans to acquire EQRx ( NASDAQ: EQRX ) in an all-stock transaction intended to add more than $1B in net cash to Revolution Medicines’ balance sheet. The deal, which...
R evolution Medicines Expect s to Conduct Late-Stage Development of RAS(ON) I nhibitor Drug C andidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independe...
2023-07-11 18:56:04 ET Summary Revolution Medicines, Inc. is undoubtedly doing interesting science. However, I can name 10 companies that are doing equally interesting science but are valued at a fifth of Revolution Medicines stock. There is no way their early data justifies t...
News, Short Squeeze, Breakout and More Instantly...
Revolution Medicines Inc. Company Name:
RVMD Stock Symbol:
NASDAQ Market:
Revolution Medicines Inc. Website:
2024-07-14 06:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Re...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) fell 9.3% to $0.2448 on volume of 58,139,351 shares NVIDIA Corporation (NVDA) rose 2.9% to $131.9 on volume of 38,975,630 shares Soligenix Inc. (SNGX) rose 189.2% to $5.784 on volume of 36,915,609...